Alzheimer Treatment News

We May Be Getting Closer to an Alzheimer’s Vaccine

View Content

A new study shows safety and potential benefit for patients with mild disease. Axon’s experimental vaccine AADVac1—currently the most clinically advanced tau therapy in development—aims to do exactly that. Its goal is to activate our bodies’ defense system to clear out free-floating tau proteins in our brains before they can form harmful tangles that accumulate inside nerve cells and eventually cause their demise.